{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T23:25:32Z","timestamp":1778196332114,"version":"3.51.4"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,7,14]],"date-time":"2020-07-14T00:00:00Z","timestamp":1594684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,7,14]],"date-time":"2020-07-14T00:00:00Z","timestamp":1594684800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"the International Cooperation Project of Guangzhou Science and Technology Program","award":["2016201604030021"],"award-info":[{"award-number":["2016201604030021"]}]},{"name":"the National Grant Program on key Infectious Disease","award":["2014ZX10002002-002"],"award-info":[{"award-number":["2014ZX10002002-002"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Complete clearance of intracellular viruses depends on effector cells of innate and adaptive immune systems. This study aimed to identify the relationships among antiviral cytokines produced by natural killer (NK) and T cells and clinical-virological characteristics in untreated chronic hepatitis B (CHB) patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We measured antiviral cytokines interferon-gamma (IFN-\u03b3), tumor necrosis factor-alpha (TNF-\u03b1), and interleukin-2 (IL-2) produced by T, NK and natural killer T (NKT) cells, respectively, in a cohort with chronic hepatitis B virus (HBV) infection (CHB). We also correlated these cytokines with clinical-virological characteristics using a linear regression model.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      levels of IFN-\u03b3\n                      <jats:sup>+<\/jats:sup>\n                      and TNF-\u03b1\n                      <jats:sup>+<\/jats:sup>\n                      CD4\n                      <jats:sup>+<\/jats:sup>\n                      and CD8\n                      <jats:sup>+<\/jats:sup>\n                      T cells were significantly higher in immune active (IA) phase than in other phases. Immune tolerant (IT) patients showed the lowest expression of IFN-\u03b3 by NK and NKT cells, and TNF-\u03b1 by NK cells. IFN-\u03b3\n                      <jats:sup>+<\/jats:sup>\n                      , TNF-\u03b1\n                      <jats:sup>+<\/jats:sup>\n                      and IL-2\n                      <jats:sup>+<\/jats:sup>\n                      CD4\n                      <jats:sup>+<\/jats:sup>\n                      and CD8\n                      <jats:sup>+<\/jats:sup>\n                      T cells frequencies were similar between IA and gray zone (GZ) phases. Principal component analysis based on cytokines confirmed that most IT patients significantly differed from inactive carriers (IC) and IA patients, while GZ patients were widely scattered. Multivariate analysis showed both T and NK cells producing IFN-\u03b3 and TNF-\u03b1, but not IL-2, had significant association with serum alanine aminotransferase (ALT). Moreover, IFN-\u03b3\n                      <jats:sup>+<\/jats:sup>\n                      NKT cells were associated with HBV DNA, while IFN-\u03b3\n                      <jats:sup>+<\/jats:sup>\n                      CD4\n                      <jats:sup>+<\/jats:sup>\n                      and CD8\n                      <jats:sup>+<\/jats:sup>\n                      T cells were correlated with age.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>HBV clinical phases are characterized by distinct cytokine signatures, which showed relationship to viral features in these untreated CHB patients.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12879-020-05233-x","type":"journal-article","created":{"date-parts":[[2020,7,14]],"date-time":"2020-07-14T10:06:56Z","timestamp":1594721216000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Association among cytokine profiles of innate and adaptive immune responses and clinical-virological features in untreated patients with chronic hepatitis B"],"prefix":"10.1186","volume":"20","author":[{"given":"Yurong","family":"Gu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yifan","family":"Lian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qiaolan","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zexuan","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lin","family":"Gu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanhua","family":"Bi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanlin","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuankai","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lubiao","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9178-8205","authenticated-orcid":false,"given":"Yuehua","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,7,14]]},"reference":[{"issue":"6","key":"5233_CR1","doi-asserted-by":"publisher","first-page":"1360","DOI":"10.1053\/j.gastro.2012.01.044","volume":"142","author":"SJ Scaglione","year":"2012","unstructured":"Scaglione SJ, Lok AS. Effectiveness of hepatitis B treatment in clinical practice. Gastroenterology. 2012;142(6):1360\u20138 e1361.","journal-title":"Gastroenterology"},{"issue":"Suppl 4","key":"5233_CR2","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1634\/theoncologist.2010-S4-05","volume":"15","author":"AP Venook","year":"2010","unstructured":"Venook AP, Papandreou C, Furuse J, de Guevara LL. The incidence and epidemiology of hepatocellular carcinoma: a global and regional perspective. Oncologist. 2010;15(Suppl 4):5\u201313.","journal-title":"Oncologist"},{"issue":"5","key":"5233_CR3","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1007\/s00535-016-1183-3","volume":"51","author":"S Yoshio","year":"2016","unstructured":"Yoshio S, Kanto T. Host-virus interactions in hepatitis B and hepatitis C infection. J Gastroenterol. 2016;51(5):409\u201320.","journal-title":"J Gastroenterol"},{"issue":"Suppl 1","key":"5233_CR4","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1111\/liv.12749","volume":"35","author":"C Ferrari","year":"2015","unstructured":"Ferrari C. HBV and the immune response. Liver Int. 2015;35(Suppl 1):121\u20138.","journal-title":"Liver Int"},{"issue":"1 Suppl","key":"5233_CR5","doi-asserted-by":"publisher","first-page":"S4","DOI":"10.1016\/j.jhep.2016.01.027","volume":"64","author":"S Tong","year":"2016","unstructured":"Tong S, Revill P. Overview of hepatitis B viral replication and genetic variability. J Hepatol. 2016;64(1 Suppl):S4\u201316.","journal-title":"J Hepatol"},{"issue":"9","key":"5233_CR6","volume":"2","author":"SA Jones","year":"2013","unstructured":"Jones SA, Hu J. Hepatitis B virus reverse transcriptase: diverse functions as classical and emerging targets for antiviral intervention. Emerg Microbes Infect. 2013;2(9):e56.","journal-title":"Emerg Microbes Infect"},{"issue":"3","key":"5233_CR7","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1002\/hep.26079","volume":"57","author":"D Paraskevis","year":"2013","unstructured":"Paraskevis D, Magiorkinis G, Magiorkinis E, Ho SY, Belshaw R, Allain JP, Hatzakis A. Dating the origin and dispersal of hepatitis B virus infection in humans and primates. Hepatology. 2013;57(3):908\u201316.","journal-title":"Hepatology"},{"issue":"4","key":"5233_CR8","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1038\/nri3818","volume":"15","author":"PA Roche","year":"2015","unstructured":"Roche PA, Furuta K. The ins and outs of MHC class II-mediated antigen processing and presentation. Nat Rev Immunol. 2015;15(4):203\u201316.","journal-title":"Nat Rev Immunol"},{"issue":"4","key":"5233_CR9","doi-asserted-by":"publisher","first-page":"277","DOI":"10.14218\/JCTH.2015.00026","volume":"3","author":"HJ Li","year":"2015","unstructured":"Li HJ, Zhai NC, Song HX, Yang Y, Cui A, Li TY, Tu ZK. The role of immune cells in chronic HBV infection. J Clin Transl Hepatol. 2015;3(4):277\u201383.","journal-title":"J Clin Transl Hepatol"},{"issue":"2","key":"5233_CR10","doi-asserted-by":"publisher","first-page":"630","DOI":"10.4049\/jimmunol.1502677","volume":"197","author":"M Yoneda","year":"2016","unstructured":"Yoneda M, Hyun J, Jakubski S, Saito S, Nakajima A, Schiff ER, Thomas E. Hepatitis B virus and DNA stimulation trigger a rapid innate immune response through NF-kappaB. J Immunol. 2016;197(2):630\u201343.","journal-title":"J Immunol"},{"key":"5233_CR11","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.coi.2015.06.016","volume":"36","author":"LG Guidotti","year":"2015","unstructured":"Guidotti LG, Isogawa M, Chisari FV. Host-virus interactions in hepatitis B virus infection. Curr Opin Immunol. 2015;36:61\u20136.","journal-title":"Curr Opin Immunol"},{"issue":"1 Suppl","key":"5233_CR12","doi-asserted-by":"publisher","first-page":"S71","DOI":"10.1016\/j.jhep.2016.01.026","volume":"64","author":"A Bertoletti","year":"2016","unstructured":"Bertoletti A, Ferrari C. Adaptive immunity in HBV infection. J Hepatol. 2016;64(1 Suppl):S71\u201383.","journal-title":"J Hepatol"},{"issue":"1","key":"5233_CR13","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.jhep.2016.07.011","volume":"66","author":"AP Benechet","year":"2017","unstructured":"Benechet AP, Iannacone M. Determinants of hepatic effector CD8+ T cell dynamics. J Hepatol. 2017;66(1):228\u201333.","journal-title":"J Hepatol"},{"issue":"12","key":"5233_CR14","doi-asserted-by":"publisher","first-page":"1754","DOI":"10.1136\/gutjnl-2011-301073","volume":"61","author":"A Bertoletti","year":"2012","unstructured":"Bertoletti A, Ferrari C. Innate and adaptive immune responses in chronic hepatitis B virus infections: towards restoration of immune control of viral infection. Gut. 2012;61(12):1754\u201364.","journal-title":"Gut"},{"key":"5233_CR15","doi-asserted-by":"publisher","first-page":"258","DOI":"10.3389\/fimmu.2014.00258","volume":"5","author":"A Schuch","year":"2014","unstructured":"Schuch A, Hoh A, Thimme R. The role of natural killer cells and CD8(+) T cells in hepatitis B virus infection. Front Immunol. 2014;5:258.","journal-title":"Front Immunol"},{"issue":"7","key":"5233_CR16","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1136\/gut.2008.163600","volume":"58","author":"P Fisicaro","year":"2009","unstructured":"Fisicaro P, Valdatta C, Boni C, Massari M, Mori C, Zerbini A, Orlandini A, Sacchelli L, Missale G, Ferrari C. Early kinetics of innate and adaptive immune responses during hepatitis B virus infection. Gut. 2009;58(7):974\u201382.","journal-title":"Gut"},{"issue":"2","key":"5233_CR17","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1053\/j.gastro.2009.09.052","volume":"138","author":"P Fisicaro","year":"2010","unstructured":"Fisicaro P, Valdatta C, Massari M, Loggi E, Biasini E, Sacchelli L, Cavallo MC, Silini EM, Andreone P, Missale G, et al. Antiviral intrahepatic T-cell responses can be restored by blocking programmed death-1 pathway in chronic hepatitis B. Gastroenterology. 2010;138(2):682\u201393 693 e681\u2013684.","journal-title":"Gastroenterology"},{"issue":"6","key":"5233_CR18","doi-asserted-by":"publisher","first-page":"1934","DOI":"10.1002\/hep.23936","volume":"52","author":"B Raziorrouh","year":"2010","unstructured":"Raziorrouh B, Schraut W, Gerlach T, Nowack D, Gruner NH, Ulsenheimer A, Zachoval R, Wachtler M, Spannagl M, Haas J, et al. The immunoregulatory role of CD244 in chronic hepatitis B infection and its inhibitory potential on virus-specific CD8+ T-cell function. Hepatology. 2010;52(6):1934\u201347.","journal-title":"Hepatology"},{"issue":"5","key":"5233_CR19","doi-asserted-by":"publisher","first-page":"1494","DOI":"10.1002\/hep.24249","volume":"53","author":"A Schurich","year":"2011","unstructured":"Schurich A, Khanna P, Lopes AR, Han KJ, Peppa D, Micco L, Nebbia G, Kennedy PT, Geretti AM, Dusheiko G, et al. Role of the coinhibitory receptor cytotoxic T lymphocyte antigen-4 on apoptosis-prone CD8 T cells in persistent hepatitis B virus infection. Hepatology. 2011;53(5):1494\u2013503.","journal-title":"Hepatology"},{"issue":"1","key":"5233_CR20","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1084\/jem.20121172","volume":"210","author":"D Peppa","year":"2013","unstructured":"Peppa D, Gill US, Reynolds G, Easom NJ, Pallett LJ, Schurich A, Micco L, Nebbia G, Singh HD, Adams DH, et al. Up-regulation of a death receptor renders antiviral T cells susceptible to NK cell-mediated deletion. J Exp Med. 2013;210(1):99\u2013114.","journal-title":"J Exp Med"},{"issue":"1","key":"5233_CR21","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1002\/hep.28156","volume":"63","author":"NA Terrault","year":"2016","unstructured":"Terrault NA, Bzowej NH, Chang KM, Hwang JP, Jonas MM, Murad MH. American Association for the Study of liver D: AASLD guidelines for treatment of chronic hepatitis B. Hepatology. 2016;63(1):261\u201383.","journal-title":"Hepatology"},{"issue":"1","key":"5233_CR22","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1002\/hep.27805","volume":"62","author":"T Vanwolleghem","year":"2015","unstructured":"Vanwolleghem T, Hou J, van Oord G, Andeweg AC, Osterhaus AD, Pas SD, Janssen HL, Boonstra A. Re-evaluation of hepatitis B virus clinical phases by systems biology identifies unappreciated roles for the innate immune response and B cells. Hepatology. 2015;62(1):87\u2013100.","journal-title":"Hepatology"},{"issue":"2","key":"5233_CR23","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1053\/j.gastro.2010.04.052","volume":"139","author":"MR Brunetto","year":"2010","unstructured":"Brunetto MR, Oliveri F, Colombatto P, Moriconi F, Ciccorossi P, Coco B, Romagnoli V, Cherubini B, Moscato G, Maina AM, et al. Hepatitis B surface antigen serum levels help to distinguish active from inactive hepatitis B virus genotype D carriers. Gastroenterology. 2010;139(2):483\u201390.","journal-title":"Gastroenterology"},{"issue":"6","key":"5233_CR24","doi-asserted-by":"publisher","first-page":"1697","DOI":"10.1002\/hep.28155","volume":"62","author":"C Boni","year":"2015","unstructured":"Boni C, Lampertico P, Talamona L, Giuberti T, Invernizzi F, Barili V, Fisicaro P, Rossi M, Cavallo MC, Vecchi A, et al. Natural killer cell phenotype modulation and natural killer\/T-cell interplay in nucleos(t) ide analogue-treated hepatitis e antigen-negative patients with chronic hepatitis B. Hepatology. 2015;62(6):1697\u2013709.","journal-title":"Hepatology"},{"issue":"3","key":"5233_CR25","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1053\/j.gastro.2012.06.009","volume":"143","author":"PT Kennedy","year":"2012","unstructured":"Kennedy PT, Sandalova E, Jo J, Gill U, Ushiro-Lumb I, Tan AT, Naik S, Foster GR, Bertoletti A. Preserved T-cell function in children and young adults with immune-tolerant chronic hepatitis B. Gastroenterology. 2012;143(3):637\u201345.","journal-title":"Gastroenterology"},{"key":"5233_CR26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fimmu.2014.00001","volume":"5","author":"R Thwaites","year":"2014","unstructured":"Thwaites R, Chamberlain G, Sacre S. Emerging role of endosomal toll-like receptors in rheumatoid arthritis. Front Immunol. 2014;5:1.","journal-title":"Front Immunol"},{"key":"5233_CR27","unstructured":"European Association for the Study of the Liver. Electronic address eee, European Association for the Study of the L: EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. J Hepatol. 2017;67(2):370\u201398."},{"issue":"3","key":"5233_CR28","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1111\/cei.12597","volume":"180","author":"Q Zheng","year":"2015","unstructured":"Zheng Q, Zhu YY, Chen J, Ye YB, Li JY, Liu YR, Hu ML, Zheng YC, Jiang JJ. Activated natural killer cells accelerate liver damage in patients with chronic hepatitis B virus infection. Clin Exp Immunol. 2015;180(3):499\u2013508.","journal-title":"Clin Exp Immunol"},{"issue":"1","key":"5233_CR29","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1053\/j.gastro.2015.09.026","volume":"150","author":"Y Xia","year":"2016","unstructured":"Xia Y, Stadler D, Lucifora J, Reisinger F, Webb D, Hosel M, Michler T, Wisskirchen K, Cheng X, Zhang K, et al. Interferon-gamma and tumor necrosis factor-alpha produced by T cells reduce the HBV persistence form, cccDNA, Without Cytolysis. Gastroenterology. 2016;150(1):194\u2013205.","journal-title":"Gastroenterology"},{"issue":"12","key":"5233_CR30","doi-asserted-by":"publisher","first-page":"1755","DOI":"10.1084\/jem.194.12.1755","volume":"194","author":"K Kakimi","year":"2001","unstructured":"Kakimi K, Lane TE, Wieland S, Asensio VC, Campbell IL, Chisari FV, Guidotti LG. Blocking chemokine responsive to gamma-2\/interferon (IFN)-gamma inducible protein and monokine induced by IFN-gamma activity in vivo reduces the pathogenetic but not the antiviral potential of hepatitis B virus-specific cytotoxic T lymphocytes. J Exp Med. 2001;194(12):1755\u201366.","journal-title":"J Exp Med"},{"issue":"5","key":"5233_CR31","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1084\/jem.178.5.1541","volume":"178","author":"K Ando","year":"1993","unstructured":"Ando K, Moriyama T, Guidotti LG, Wirth S, Schreiber RD, Schlicht HJ, Huang SN, Chisari FV. Mechanisms of class I restricted immunopathology. A transgenic mouse model of fulminant hepatitis. J Exp Med. 1993;178(5):1541\u201354.","journal-title":"J Exp Med"},{"issue":"1","key":"5233_CR32","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.jhep.2011.06.028","volume":"56","author":"SA Lee","year":"2012","unstructured":"Lee SA, Kim K, Kim H, Kim BJ. Nucleotide change of codon 182 in the surface gene of hepatitis B virus genotype C leading to truncated surface protein is associated with progression of liver diseases. J Hepatol. 2012;56(1):63\u20139.","journal-title":"J Hepatol"},{"issue":"7","key":"5233_CR33","doi-asserted-by":"publisher","first-page":"2635","DOI":"10.4049\/jimmunol.1600974","volume":"197","author":"JM Stolley","year":"2016","unstructured":"Stolley JM, Campbell DJ. A 33D1+ dendritic cell\/autoreactive CD4+ T cell circuit maintains IL-2-dependent regulatory T cells in the spleen. J Immunol. 2016;197(7):2635\u201345.","journal-title":"J Immunol"},{"issue":"4","key":"5233_CR34","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/S2213-8587(13)70113-X","volume":"1","author":"A Hartemann","year":"2013","unstructured":"Hartemann A, Bensimon G, Payan CA, Jacqueminet S, Bourron O, Nicolas N, Fonfrede M, Rosenzwajg M, Bernard C, Klatzmann D. Low-dose interleukin 2 in patients with type 1 diabetes: a phase 1\/2 randomised, double-blind, placebo-controlled trial. Lancet Diabetes Endocrinol. 2013;1(4):295\u2013305.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"5","key":"5233_CR35","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1038\/nri3823","volume":"15","author":"D Klatzmann","year":"2015","unstructured":"Klatzmann D, Abbas AK. The promise of low-dose interleukin-2 therapy for autoimmune and inflammatory diseases. Nat Rev Immunol. 2015;15(5):283\u201394.","journal-title":"Nat Rev Immunol"},{"issue":"6","key":"5233_CR36","doi-asserted-by":"publisher","first-page":"2172","DOI":"10.2337\/db14-1322","volume":"64","author":"A Yu","year":"2015","unstructured":"Yu A, Snowhite I, Vendrame F, Rosenzwajg M, Klatzmann D, Pugliese A, Malek TR. Selective IL-2 responsiveness of regulatory T cells through multiple intrinsic mechanisms supports the use of low-dose IL-2 therapy in type 1 diabetes. Diabetes. 2015;64(6):2172\u201383.","journal-title":"Diabetes"},{"key":"5233_CR37","first-page":"651","volume":"6","author":"MN Pham","year":"2015","unstructured":"Pham MN, von Herrath MG, Vela JL. Antigen-specific regulatory T cells and low dose of IL-2 in treatment of type 1 diabetes. Front Immunol. 2015;6:651.","journal-title":"Front Immunol"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-020-05233-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12879-020-05233-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-020-05233-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,13]],"date-time":"2021-07-13T19:14:24Z","timestamp":1626203664000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/s12879-020-05233-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,14]]},"references-count":37,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["5233"],"URL":"https:\/\/doi.org\/10.1186\/s12879-020-05233-x","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.2.11667\/v2","asserted-by":"object"},{"id-type":"doi","id":"10.21203\/rs.2.11667\/v1","asserted-by":"object"},{"id-type":"doi","id":"10.21203\/rs.2.11667\/v3","asserted-by":"object"}]},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,14]]},"assertion":[{"value":"8 July 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 July 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 July 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"We have read and complied with the policy of the journal on ethical consent, as stated in the Guide to Authors. The study was approved by the Institutional Review Board of the Sun Yat-sen University, and the work was carried out in accordance with The Code of Ethics of the World Medical Association (Declaration of Helsinki) for experiments involving humans and Uniform Requirements for Manuscripts Submitted to Biomedical journals. Written informed consent was obtained from all patients. The privacy rights of human subjects were always observed.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"509"}}